Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Current guidelines advise against using embryos derived from mono-pronuclei (1PN) or non-pronuclei (0PN) zygotes for clinical purposes. Nevertheless, recent studies have demonstrated that 1PN and 0PN zygotes can lead to healthy births. This study aimed to investigate the pregnancy outcomes of 1PN and 0PN blastocysts.
Methods: PubMed, EMBASE, Web of Science and Cochrane databases were searched up to 14 March 2024. Eligible studies enrolled participants transferring 0PN or 1PN blastocysts, with two pronuclei (2PN) blastocysts used as the control. Clinical pregnancy rate, miscarriage rate and live birth rate were the main outcomes. The results were presented as odds ratios (OR) with 95 % confidence intervals (CI) using random-effect models with the Mantel-Haenszel method. Additionally, a stratified analysis was conducted based on the type of fertilization. The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the included studies.
Results: In total, 270 articles were identified, with 16 ultimately included in the meta-analysis. In total, 57,835 cycles were analysed: 1071 cycles in the 1PN group, 2324 cycles in the 0PN group, and 54,440 cycles in the 2PN group. The results indicated that 1PN or 0PN blastocysts were associated with lower clinical pregnancy rates and live birth rates than 2PN blastocysts. Interestingly, there was no significant difference in live birth rate between 1PN blastocysts and 2PN blastocysts in patients undergoing intracytoplasmic sperm injection (ICSI), nor between 0PN blastocysts and 2PN blastocysts in patients undergoing in-vitro fertilization (IVF).
Conclusion: Careful consideration should be given to the utilization of 1PN and 0PN blastocysts, especially if an improved methodology of non-invasive assessment of fertilization is available. At the very least, 1PN blastocysts in patients undergoing ICSI and 0PN blastocysts in patients undergoing IVF represent viable fertility options for patients facing abnormal fertilization in clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11981765 | PMC |
| http://dx.doi.org/10.1016/j.eurox.2025.100381 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Could blastocysts derived from abnormal fertilized zygotes be used? A systematic review and meta-analysis.
Eur J Obstet Gynecol Reprod Biol
July 2025
Women's Reproductive Health Research Key Laboratory of Zhejiang Province and Department of Reproductive Endocrinology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China; Key Laboratory of Reproductive Genetics (Zhejiang University), Ministry of Education, Hangzho
Objectives: Current guidelines advise against using embryos derived from mono-pronuclei (1PN) or non-pronuclei (0PN) zygotes for clinical purposes. Nevertheless, recent studies have demonstrated that 1PN and 0PN zygotes can lead to healthy births. This study aimed to investigate the pregnancy outcomes of 1PN and 0PN blastocysts.
View Article and Find Full Text PDFThe use of blastocysts developing from nonpronuclear and monopronuclear zygotes can be considered in PGT-SR: a retrospective cohort study.
BMC Pregnancy Childbirth
May 2025
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Reproductive Medicine, Cheeloo College of Medicine, Institute of Women, Children and Reproductive Health, Shandong University, 157 Jingliu Road, Jinan, 250012, Shandong, China.
Background: While zygotes lacking pronuclei (0PN) or exhibiting a single pronucleus (1PN) may theoretically yield diploid embryos with developmental potential, current clinical protocols predominantly exclude these embryos from use. In the population undergoing preimplantation genetic testing for structural rearrangements (PGT-SR), there is a high rate of chromosomal aneuploidy abnormalities and needs a large number of embryos to obtain euploid embryos, so we will explore whether 0PN and 1PN embryos can be an option for them.
Methods: This retrospective analysis examined pronuclear development in 4,868 zygotes derived from 4,902 injected metaphase II (MII) oocytes across 422 assisted reproductive cycles.
Could blastocysts derived from abnormal fertilized zygotes be used? A systematic review and meta-analysis.
Eur J Obstet Gynecol Reprod Biol X
June 2025
Women's Reproductive Health Research Key Laboratory of Zhejiang Province and Department of Reproductive Endocrinology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR China.
Objectives: Current guidelines advise against using embryos derived from mono-pronuclei (1PN) or non-pronuclei (0PN) zygotes for clinical purposes. Nevertheless, recent studies have demonstrated that 1PN and 0PN zygotes can lead to healthy births. This study aimed to investigate the pregnancy outcomes of 1PN and 0PN blastocysts.
View Article and Find Full Text PDFThe Identification of Molecular Ploidy Status of Abnormal Pronuclear Zygotes Reveals a Significant Number of Euploid Blastocysts Available for Conception.
Biomedicines
December 2024
CCRM Genetics, 10290 Ridgegate Circle, Lone Tree, CO 80124, USA.
Abnormally fertilized embryos are often discarded during in vitro fertilization due to the fact that known chromosomal ploidy abnormalities lead to implantation failure or pregnancy loss. The objective of this study was to determine if pronuclear numeration (PN) observed at fertilization check is representative of the true ploidy status of the subsequent developing blastocyst in order to maximize the number of viable embryos available for infertility patients and increase their chances of conception. Upon successful fertilization, pronuclear numeration was noted, and zygotes were cultured to the blastocyst stage.
View Article and Find Full Text PDFUse of time-lapse technology on fertilization verification, embryo evaluation, and utilization: A national survey in Japan.
AJOG Glob Rep
November 2024
JSRM SIG embryology (Special Interest Group of Embryology in Japan Society Reproductive Medicine), Tokyo 100-0014, Japan (Yamada, Ezoe, Ueno, Yoshino, and Takahashi).
Background: Time-lapse technology (TLT) has emerged as a significant advancement in the field of assisted reproductive technology (ART), providing continuous observation of embryos. However, limited information exists on the adoption of TLT across ART facilities and the clinical implications of its application in embryo evaluation and fertilization verification. The existing literature has not yet comprehensively examined how TLT data are utilized to optimize ART outcomes, particularly in Japan, where ART practices are highly prevalent.
View Article and Find Full Text PDF